Stryker (SYK) Q3 2026 (USD): Adj. EPS 3.52 (exp. 3.55), Revenue 6.5bln (exp. 6.62bln); to increase share buyback by USD 5bln

• FY adj. EPS view 14.80-14.90 (exp. 14.95).

Prints of this kind from large-cap medtech have historically been decided by the guidance rather than the quarter itself, and a modest miss on both lines paired with a full-year view set below consensus fits the template that has tended to produce negative opening gaps for high-multiple quality names in the sector. Stryker's established form has been that of a beat-and-raise operator, which makes a below-consensus outlook a more consequential departure than the same print would be from a peer with a looser track record. The enlarged buyback authorization alongside a soft report is a familiar cushioning device; authorizations of this size are typically executed over multiple years and have tended to mute rather than reverse the initial reaction, with the distinction between headline authorization and actual repurchase pace mattering for any sustained support. The operative questions sit on the call: procedure volumes and capital equipment demand, particularly robotic platform placements, since a volume-driven shortfall reads across to orthopedic peers while a mix or supply-driven one stays idiosyncratic. Whether the full-year revenue outlook was trimmed alongside EPS, and how management frames margins against tariff and supply-chain commentary, will separate a conservative reset from a genuine demand signal. As a first read, the pattern is mildly negative with the buyback limiting the downside precedent.